Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings. RWE evidence-strategy director in a company with a CMC site change mid-review has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend Proceed under protocol from advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend Proceed under protocol from advisory-committee question list that exposes a weak secondary endpoint; Pause the pathway is what the extract actually supports after an AdCom briefing document that overstates subgroup findings. 3. An AdCom briefing document that overstates subgroup findings never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close to drop a secondary. 4. Two facts in advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings conflict for RWE evidence-strategy director; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a company with a CMC site change mid-review.